Corporate News
Darwin AG publishes issuer report for the first half of 2024
München, 15.10.2024
Darwin AG (ISIN DE000A3C35W0) today published the issuer report as of June 30, 2024.
"In the first half of the year, we succeeded in setting important course for expanding the sales of our personalized nutritional supplements and cosmetics," reports CEO Dr. Daniel Wallerstorfer. "This means that we are very well prepared for the sales growth planned for the second half of the year and are optimistic about the future despite the currently difficult economic situation" the company founder continued.
The report is available for download athttps://darwin-biotech.com/financial-reports/.
Background
The "Darwin Group" (i.e. Darwin AG including its subsidiaries), headquartered in Munich (Germany), is a European biotechnology company, particularly in the field of human genetics. The genetic analyzes carried out in our own laboratory are used in diagnostics, therapy and prevention of diseases as well as in the production of individually designed nutritional supplements and cosmetics. Darwin also acts as a partner for doctors, therapists, pharmacists, nutritionists or fitness trainers and, by analyzing the respective genetic predisposition of the patient or customer, helps to ensure the best possible treatment or care for their needs. Darwin also invests in innovative companies in the biotech, healthcare and life sciences sectors.
Contact:
Darwin AG
Brienner Str. 7
80333 München
Tel: +49 89 / 20 500 450
investor.relations@darwin-biotech.com